Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2013; 110(04): 852-853
DOI: 10.1160/TH13-05-0393
DOI: 10.1160/TH13-05-0393
Letters to the Editor
Evaluation of a commercial assay for ADAMTS13 activity measurement
Financial Support: This work was partially supported by a grant from the Délégation Régionale à la Recherche Clinique, Assistance Publique-Hôpitaux de Paris (PHRC AOM05012) and declared at ClinicalTrials.gov record (http://clinicaltrials.gov/show/NCT00426686, study ID number: P051064, Health Authority: France, Ministry of Health).Further Information
Publication History
Received:
15 May 2013
Accepted after minor revision:
07 June 2013
Publication Date:
01 December 2017 (online)
-
References
- 1 Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3: 249-277.
- 2 Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91: 1-19.
- 3 Kremer-Hovinga J, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2012; 2012: 610-616.
- 4 Mackie I, Langley K, Chitolie A. et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 2013; 109: 488-496.
- 5 Moatti-Cohen M, Garrec C, Wolf M. et al. for the French Refrence Center for Thrombotic Microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119: 5888-5897.
- 6 Kokame K, Nobe Y, Kokubo Y. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.